ImunoTera was founded by three researchers who developed a platform of therapeutic vaccines capable of restoring and activating the immune system to fight infectious diseases and cancer. The platform is based on a dual-function recombinant protein that can be engineered to target different types of cancer and infectious diseases. This system acts by antigen-loading and activating dendritic cells leading to the generation of target-specific cytotoxic T lymphocytes (CTL), while blocking immunosuppressive pathways. The pipeline so far includes therapeutic vaccines to control HPV-related cancer, HIV, ZIKV, and SARS-CoV-2. Our company has been pursuing therapeutic strategies targeting HPV-induced tumors such as cervical and head and neck cancers Our first product, the TERAH-7 is currently being applied in an experimental clinical showing complete regression of CIN, and HPV clearance and avoiding the need for surgery in some treated patients. In 2020, ImunoTera was one of the winners of the Innovative Women Award promoted by the Financier of Studies and Projects (Finep) related to the Brazilian Ministry of Science and Technology. In 2023, ImunoTera was Top 30 in Latin America finalists for the Bayer Foundation Women Empowerment Award. Currently, ImunoTera is part of the portfolio of companies incubated at Hospital Israelita Albert Einstein, considered the best hospital in Latin America. | ImunoTera has developed a platform of active immunotherapies that teach the immune system to recognize and eliminate cancer cells, also generating a long-term memory capable of avoiding recurrences and metastases. The first product, called TERAH-7, is a therapeutic vaccine aimed at treating cancer caused by HPV, such as cervical cancer.
IMS Brazil
Welcome to IMS Brazil, where tradition meets innovation in pet care. With roots tracing back to the 1970s, we’re pioneers in the manufacture treats for dogs, using only the finest sources. Our commitment to excellence means providing health and incomparable flavor in the finest quality chews, natural and without any chemicals. Join us in elevating pet care standards with IMS Brazil – where every product embodies our dedication to pet ́s well-being.
IMPLY BOWLING
Present in 125+ countries, Imply® Bowling is recognized worldwide as one of the leading Bowling brands. With Imply®, you gain access to cutting-edge technological advancements, unmatched performance and the industry’s lowest operating costs. We will plan, design, manufacture and install the ideal Bowling Alleys for you, with Official or Customized dimensions. Make the right choice. Choose Imply® and embark on the journey towards the success of your Bowling.
IGC
Global manufacturer of instant coffee and related products, and one of the largest exporters in the world.
ICC Animal Nutrition
ICC Animal Nutrition is Brazil’s largest producer of natural, sustainable solutions based on Saccharomyces cerevisiae yeasts from sugarcane ethanol fermentation, and one of the world’s leading manufacturers of engineered yeast products. With over 30 years of experience, ICC Animal Nutrition is a global reference in yeast-based solutions and a scientific leader in research and the development of proven nutritional strategies to improve animal performance, health, and welfare. Present in more than 70 countries across five continents, ICC contributes to safer, more efficient animal production and helps meet the growing global demand for quality and affordable food.
Hypera Pharma
A giant in the brazilian market, Hypera Pharma is the largest brazilian pharmaceutical company, owner of a strong portfolio of non-replicable leading brands in Brazil including 21 power brands. Hypera is looking for strategic players to partner in improving our portfolio with novel pharma and innovative technologies. | Hypera Pharma is one of the biggest and most diversified pharmaceutical companies in Brazil. It’s present in all relevant segments of the retail pharmaceutical sector in Brazil, with leadership in several product categories. The company offers high-quality products, and keeps investing in innovation to grow in a sustainable way. The strength of the Company in the pharmaceutical market is supported by a large-scale and low-cost operation based in the largest pharmaceutical operating complex in Latin America, located in Anápolis, Goiás. It is a 120,000-square meter structure with more than 9,000 employees. Annually it produces more than 650 million solid doses, 20 million units of injectable drugs and eye drops, more than 250 million units of vitamins and 300 million units of liquids, creams, oils and lotions. To support constant innovation in its business, the Company created in 2017 Hynova, the most modern pharmaceutical research center in Brazil, which houses a team of highly qualified professionals, masters and doctors for the development of medicines, dermocosmetics and nutraceuticals, using cutting-edge technology to be a pioneer in Brazil. The Company also has a broad national sales and distribution structure. Its products are distributed throughout Brazil, directly to retailers, or indirectly through distributors and wholesalers. Founded in 2001 as Hypermarcas, its corporate name changed in 2017 to Hypera Pharma, evidencing the Company’s new focus in the pharmaceutical market. It is listed in B3’s Novo Mercado since 2008 and currently employs around 10,000 people.
Huna
Supercharging routine blood exams with AI, Huna turns massive data into accessible cancer care. By partnering with global leaders and leveraging one of the world’s largest oncology datasets, we deliver scalable solutions for early detection and risk stratification. Our platform supports the full cancer journey—from triage to diagnosis and beyond—transforming standard lab data into powerful clinical insights. Huna makes cutting-edge innovation usable by real-world healthcare systems tackling one of the world’s biggest health challenges.